The invention is directed to a method of inhibiting bone resorption. The method comprises administering to a human an amount of sclerostin inhibitor that reduces a bone resorption marker level for at least 2 weeks. The invention also provides a method of monitoring anti-sclerostin therapy comprising
The invention is directed to a method of inhibiting bone resorption. The method comprises administering to a human an amount of sclerostin inhibitor that reduces a bone resorption marker level for at least 2 weeks. The invention also provides a method of monitoring anti-sclerostin therapy comprising measuring one or more bone resorption marker levels, administering a sclerostin binding agent, then measuring the bone resorption marker levels. Also provided is a method of increasing bone mineral density; a method of ameliorating the effects of an osteoclast-related disorder; a method of treating a bone-related disorder by maintaining bone density; and a method of treating a bone-related disorder in a human suffering from or at risk of hypocalcemia or hypercalcemia, a human in which treatment with a parathyroid hormone or analog thereof is contraindicated, or a human in which treatment with a bisphosphonate is contraindicated.
대표청구항▼
1. A method for administering an anti-sclerostin antibody to a human in need thereof, the method comprising administering to said human from about 1 mg/kg to about 8 mg/kg of a monoclonal anti-sclerostin antibody that demonstrates a binding affinity for sclerostin of SEQ ID NO:1 of less than or equa
1. A method for administering an anti-sclerostin antibody to a human in need thereof, the method comprising administering to said human from about 1 mg/kg to about 8 mg/kg of a monoclonal anti-sclerostin antibody that demonstrates a binding affinity for sclerostin of SEQ ID NO:1 of less than or equal to 10−9 M, wherein said monoclonal antibody cross-blocks the binding of an antibody comprising heavy chains of SEQ ID NO:209 and light chains of SEQ ID NO:205 to sclerostin and/or is cross-blocked from binding to sclerostin by an antibody comprising heavy chains of SEQ ID NO:209 and light chains of SEQ ID NO:205. 2. The method of claim 1, wherein the anti-sclerostin antibody is administered at about 2 mg/kg. 3. The method of claim 1, wherein the anti-sclerostin antibody is administered once every two weeks. 4. The method of claim 1, wherein the anti-sclerostin antibody is administered once per month. 5. The method of claim 2, wherein the anti-sclerostin antibody is administered once every two weeks. 6. The method of claim 2, wherein the anti-sclerostin antibody is administered once per month. 7. The method of any one of claims 1-6 wherein the human is a post-menopausal woman. 8. The method of any one of claims 1-6 wherein the human is suffering from osteoporosis. 9. The method of any one of claims 1-6 wherein the human is suffering from a bone-related disorder selected from the group consisting of achondroplasia, cleidocranial dysostosis, enchondromatosis, fibrous dysplasia, Gaucher's Disease, hypophosphatemic rickets, Marfan's syndrome, multiple hereditary exotoses, neurotibromatosis, osteogenesis imperfecta, osteopetrosis, osteopoikilosis, sclerotic lesions, pseudoarthrosis, pyogenic osteomyelitis, periodontal disease, anti-epileptic drug induced bone loss, primary and secondary hyperparathyroidism, familial hyperparathyroidism syndromes, weightlessness induced bone loss, osteoporosis in men, postmenopausal bone loss, osteoarthritis, renal osteodystrophy, infiltrative disorders of bone, oral bone loss, osteonecrosis of the jaw, juvenile Paget's disease, melorheostosis, metabolic bone diseases, mastocytosis, sickle cell anemia/disease, organ transplant related bone loss, kidney transplant related bone loss, systemic lupus erythematosus, ankylosing spondylitis, epilepsy, juvenile arthritides, thalassemia, mucopolysaccharidoses, Fabry Disease, Turner Syndrome, Down Syndrome, Klinefelter Syndrome, leprosy, Perthes' Disease, adolescent idiopathic scoliosis, infantile onset multi-system inflammatory disease, Winchester Syndrome, Menkes Disease, Wilson's Disease, ischemic bone disease, Legg-Calve-Perthes disease, regional migratory osteoporosis, anemic states, conditions caused by steroids, glucocorticoid-induced bone loss, heparin-induced bone loss, bone marrow disorders, scurvy, malnutrition, calcium deficiency, osteopenia, alcoholism, chronic liver disease, postmenopausal state, chronic inflammatory conditions, rheumatoid arthritis, inflammatory bowel disease, ulcerative colitis, inflammatory colitis, Crohn's disease, oligomenorrhea, amenorrhea, pregnancy, diabetes mellitus, hyperthyroidism, thyroid disorders, parathyroid disorders, Cushing's disease, acromegaly, hypogonadism, immobilization or disuse, reflex sympathetic dystrophy syndrome, regional osteoporosis, osteomalacia, bone loss associated with joint replacement, HIV associated bone loss, bone loss associated with loss of growth hormone, bone loss associated with cystic fibrosis, chemotherapy associated bone loss, tumor induced bone loss, cancer-related bone loss, hormone ablative bone loss, multiple myeloma, drug-induced bone loss, anorexia nervosa, disease associated facial bone loss, disease associated cranial bone loss, disease associated bone loss of the jaw, disease associated bone loss of the skull, bone loss associated with aging, facial bone loss associated with aging, cranial bone loss associated with aging, jaw bone loss associated with aging, skull bone loss associated with aging, and bone loss associated with space travel. 10. The method of any one of claims 1-6, wherein the antibody is a human antibody, a humanized antibody, or a chimeric antibody. 11. The method of any one of claims 1-6, wherein the human is suffering from a bone-related disorder. 12. The method of claim 1, comprising administering to said human from about 1 mg/kg to about 3 mg/kg of an anti-sclerostin antibody. 13. The method of claim 1, wherein the anti-sclerostin antibody is administered to said human in an amount from about 70 mg to about 450 mg. 14. The method of claim 13, wherein the amount of anti-sclerostin antibody administered to said human is about 70 mg. 15. The method of claim 13, wherein the amount of anti-sclerostin antibody administered to said human is about 140 mg. 16. The method of claim 13, wherein the amount of anti-sclerostin antibody administered to said human is about 210 mg. 17. The method of claim 7, wherein the anti-sclerostin antibody is administered to said human in an amount from about 70 mg to about 450 mg. 18. The method of claim 8, wherein the anti-sclerostin antibody is administered to said human in an amount from about 70 mg to about 450 mg.
연구과제 타임라인
LOADING...
LOADING...
LOADING...
LOADING...
LOADING...
이 특허에 인용된 특허 (53)
Btzow Ralf (Helsinki CA FIX) Ruoslahti Erkki (Rancho Santa Fe CA), 60 kDa transforming growth factor-b
상세보기
Brunkow, Mary E.; Galas, David J.; Kovacevich, Brian; Mulligan, John T.; Paeper, Bryan W.; Van Ness, Jeffrey; Winkler, David G., Antibodies associated with alterations in bone density.
Brunkow, Mary E; Galas, David J; Kovacevich, Brian; Mulligan, John T; Paeper, Bryan W; Van Ness, Jeffrey; Winkler, David G, Antibodies associated with alterations in bone density.
Dan Michael D.,CAX ; Maiti Pradip K.,CAX ; Kaplan Howard A.,CAX, Antigen binding fragments that specifically detect cancer cells, nucleotides encoding the fragments, and use thereof for the prophylaxis and detection of cancers.
Brunkow, Mary E; Galas, David J; Kovacevich, Brian; Mulligan, John T; Paeper, Bryan; Van Ness, Jeffrey; Winkler, David G, Compositions and methods for increasing bone mineralization.
Mary E. Brunkow ; David J. Galas ; Brian Kovacevich ; John T. Mulligan ; Bryan W. Paeper ; Jeffrey Van Ness ; David G. Winkler, Compositions and methods for increasing bone mineralization.
Ladner Robert C. (Ijamsville MD) Guterman Sonia K. (Belmont MA) Roberts Bruce L. (Milford MA) Markland William (Milford MA) Ley Arthur C. (Newton MA) Kent Rachel B. (Boxborough MA), Directed evolution of novel binding proteins.
Yagi Kunio (Aichi-ken JPX) Noda Hitoshi (Aichi-ken JPX) Ohishi Nobuko (Gifu JPX) Kurono Masayasu (Mie-ken JPX), Liposome for entrapping gene, liposomal preparation and process for the manufacture of the preparation.
Stemmer Willem P. C. ; Crameri Andreas, Methods for generating polynucleotides having desired characteristics by iterative selection and recombination.
Margolis David J. (Philadelphia PA), Methods of treating osteoporosis, increasing bone mineral content and preventing the occurrence of compression fractures.
Mary E. Brunkow ; David J. Galas ; Brian Kovacevich ; John T. Mulligan ; Bryan W. Paeper ; Jeffrey Van Ness ; David G. Winkler, Nucleic acids encoding a novel family of TGF-.beta. binding proteins from humans.
Mary E. Brunkow ; David J. Galas ; Brian Kovacevich ; John T. Mulligan ; Bryan W. Paeper ; Jeffrey Van Ness ; David G. Winkler, Polypeptides associated with alterations in bone density.
Liversidge Gary G. (West Chester PA) Cundy Kenneth C. (Pottstown PA) Bishop John F. (Rochester NY) Czekai David A. (Honeoye Falls NY), Surface modified drug nanoparticles.
Goldenberg Milton D. (11837 Gainsborough Rd. Potomac MD 20854), Tumor localization and therapy with labeled antibody fragments specific to tumor-associated markers.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.